Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
131M
-
Shares change
-
+8.25M
-
Total reported value, excl. options
-
$586M
-
Value change
-
+$41.7M
-
Put/Call ratio
-
0.47
-
Number of buys
-
73
-
Number of sells
-
-73
-
Price
-
$4.47
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q1 2024
193 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q1 2024.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 131M shares
of 226M outstanding shares and own 58% of the company stock.
Largest 10 shareholders include FMR LLC (25.4M shares), TPG GP A, LLC (18.7M shares), BlackRock Inc. (9.65M shares), STATE STREET CORP (9.18M shares), VANGUARD GROUP INC (8.21M shares), PRIMECAP MANAGEMENT CO/CA/ (5.45M shares), JPMORGAN CHASE & CO (5.18M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.18M shares), Boxer Capital, LLC (3.85M shares), and CITADEL ADVISORS LLC (3.11M shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.